These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 17890246

  • 1. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure.
    Othersen JB, Maize JC, Woolson RF, Budisavljevic MN.
    Nephrol Dial Transplant; 2007 Nov; 22(11):3179-85. PubMed ID: 17890246
    [Abstract] [Full Text] [Related]

  • 2. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
    Wiginton CD, Kelly B, Oto A, Jesse M, Aristimuno P, Ernst R, Chaljub G.
    AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
    [Abstract] [Full Text] [Related]

  • 3. An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital.
    Marckmann P.
    Eur J Radiol; 2008 May; 66(2):187-90. PubMed ID: 18328659
    [Abstract] [Full Text] [Related]

  • 4. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.
    Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS.
    J Am Soc Nephrol; 2006 Sep; 17(9):2359-62. PubMed ID: 16885403
    [Abstract] [Full Text] [Related]

  • 5. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure.
    Todd DJ, Kagan A, Chibnik LB, Kay J.
    Arthritis Rheum; 2007 Oct; 56(10):3433-41. PubMed ID: 17907148
    [Abstract] [Full Text] [Related]

  • 6. Gadolinium-associated nephrogenic systemic fibrosis.
    Schlaudecker JD, Bernheisel CR.
    Am Fam Physician; 2009 Oct 01; 80(7):711-4. PubMed ID: 19817341
    [Abstract] [Full Text] [Related]

  • 7. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent.
    Rydahl C, Thomsen HS, Marckmann P.
    Invest Radiol; 2008 Feb 01; 43(2):141-4. PubMed ID: 18197066
    [Abstract] [Full Text] [Related]

  • 8. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
    Kallen AJ, Jhung MA, Cheng S, Hess T, Turabelidze G, Abramova L, Arduino M, Guarner J, Pollack B, Saab G, Patel PR.
    Am J Kidney Dis; 2008 Jun 01; 51(6):966-75. PubMed ID: 18501784
    [Abstract] [Full Text] [Related]

  • 9. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
    Boyd AS, Sanyal S, Abraham JL.
    J Am Acad Dermatol; 2010 Feb 01; 62(2):337-42. PubMed ID: 19939504
    [Abstract] [Full Text] [Related]

  • 10. Nephrogenic systemic fibrosis: a report of 29 cases.
    Shabana WM, Cohan RH, Ellis JH, Hussain HK, Francis IR, Su LD, Mukherji SK, Swartz RD.
    AJR Am J Roentgenol; 2008 Mar 01; 190(3):736-41. PubMed ID: 18287446
    [Abstract] [Full Text] [Related]

  • 11. Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness.
    Canavese C, Mereu MC, Aime S, Lazzarich E, Fenoglio R, Quaglia M, Stratta P.
    J Nephrol; 2008 Mar 01; 21(3):324-36. PubMed ID: 18587720
    [Abstract] [Full Text] [Related]

  • 12. [Nephrogenic systemic fibrosis: another problem for patients with chronic renal failure].
    Michelet PR, Chopard CS, Martin PY, Vallée JP.
    Rev Med Suisse; 2008 Mar 05; 4(147):576-8, 580. PubMed ID: 18402015
    [Abstract] [Full Text] [Related]

  • 13. Nephrogenic systemic fibrosis in advanced chronic kidney disease: a single hospital's experience in Taiwan.
    Chen W, Huang SL, Huang CS, Tsai MC, Lai HM, Lui CC, Eng HL, Chang HW, Lee CH, Chuang FR.
    Eur J Dermatol; 2009 Mar 05; 19(1):44-9. PubMed ID: 19059824
    [Abstract] [Full Text] [Related]

  • 14. Nephrogenic systemic fibrosis: a clinicopathologic study of six cases.
    Pryor JG, Poggioli G, Galaria N, Gust A, Robison J, Samie F, Hanjani NM, Scott GA.
    J Am Acad Dermatol; 2007 Jul 05; 57(1):105-11. PubMed ID: 17412451
    [Abstract] [Full Text] [Related]

  • 15. A follow-up of four cases of nephrogenic systemic fibrosis: is gadolinium the specific trigger?
    Singh M, Davenport A, Clatworthy I, Lewin J, Deroide F, Hubbard V, Rustin MH.
    Br J Dermatol; 2008 Jun 05; 158(6):1358-62. PubMed ID: 18363754
    [Abstract] [Full Text] [Related]

  • 16. The impact of NSF on the care of patients with kidney disease.
    Abu-Alfa A.
    J Am Coll Radiol; 2008 Jan 05; 5(1):45-52. PubMed ID: 18180009
    [Abstract] [Full Text] [Related]

  • 17. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure.
    Grobner T, Prischl FC.
    Semin Dial; 2008 Jan 05; 21(2):135-9. PubMed ID: 18226001
    [Abstract] [Full Text] [Related]

  • 18. Nephrogenic systemic fibrosis: an overview.
    Cowper SE.
    J Am Coll Radiol; 2008 Jan 05; 5(1):23-8. PubMed ID: 18180005
    [Abstract] [Full Text] [Related]

  • 19. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis.
    Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P.
    Br J Dermatol; 2008 Feb 05; 158(2):273-80. PubMed ID: 18067485
    [Abstract] [Full Text] [Related]

  • 20. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy.
    Kribben A, Witzke O, Hillen U, Barkhausen J, Daul AE, Erbel R.
    J Am Coll Cardiol; 2009 May 05; 53(18):1621-8. PubMed ID: 19406336
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.